Compare CSTL & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSTL | BCSF |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 838.7M |
| IPO Year | 2019 | 2015 |
| Metric | CSTL | BCSF |
|---|---|---|
| Price | $33.05 | $10.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $45.22 | $12.63 |
| AVG Volume (30 Days) | 319.5K | ★ 514.2K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 18.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $8.49 | N/A |
| Revenue Next Year | $10.44 | N/A |
| P/E Ratio | ★ N/A | $37.83 |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $17.72 | $10.00 |
| 52 Week High | $44.28 | $14.70 |
| Indicator | CSTL | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 30.87 |
| Support Level | $31.44 | N/A |
| Resistance Level | $34.23 | $13.74 |
| Average True Range (ATR) | 1.69 | 0.24 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 21.52 | 8.96 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.